4-O-(2,3,4-tetra-O-benzyl-β-D-glucopyranosyl)-2,3,6-tri-O-benzyl-D-glucopyranose | 108811-21-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-O-(2,3,4-tetra-O-benzyl-β-D-glucopyranosyl)-2,3,6-tri-O-benzyl-D-glucopyranose
• 英文别名: 2,3,6-tri-O-benzyl-4-O-(2,3,4,6-tetra-O-beznyl-β-D-galactopyranosyl)-α-D-glucopyranose；2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl-(1→4)-2,3,6-tri-O-benzyl-α-D-glucopyranose；2,3,6-tri-O-benzyl-4-O-(2′,3′,4′,6′-tetra-O-benzyl-β-D-glucopyranosyl)-α-glucopyranose；2,3,6,2',3',4',6'-hepta-O-benzyl-α-D-cellobiose；Bn(-2)[Bn(-3)][Bn(-4)][Bn(-6)]Glc(b1-4)[Bn(-2)][Bn(-3)][Bn(-6)]a-Glc；(2S,3R,4S,5R,6R)-3,4-bis(phenylmethoxy)-6-(phenylmethoxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-tris(phenylmethoxy)-6-(phenylmethoxymethyl)oxan-2-yl]oxyoxan-2-ol
• CAS: 108811-21-8
• 化学式: C₆₁H₆₄O₁₁
• 分子量: 973.173
• InChiKey: XOACCKXXDCYYAW-KGSXZNPLSA-N

物化性质

• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  8.9
• 重原子数：
  72
• 可旋转键数：
  25
• 环数：
  9.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  113
• 氢给体数：
  1
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  4-O-(2,3,4-tetra-O-benzyl-β-D-glucopyranosyl)-2,3,6-tri-O-benzyl-D-glucopyranose 在 palladium on activated charcoal 氯化亚砜 、 4 A molecular sieve 、 氢气 、 N,N-二甲基甲酰胺 、 mercury dibromide 作用下， 以 甲醇 、 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 48.0h， 生成 1-O-(4-O-β-D-glucopyranosyl-α-D-glucopyranosyl)-3-deoxy-2(S)-glycerol
  参考文献：
  名称：

  Sugawara, Fumio; Nakayama, Haruhiko; Stroebel, Gary A., Agricultural and Biological Chemistry, 1986, vol. 50, # 9, p. 2261 - 2272

  摘要：

  DOI：
• 作为产物：
  描述：

  Allyl β-cellobioside 在 sodium hydride 、 palladium dichloride 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 、 paraffin 为溶剂， 反应 2.0h， 生成 4-O-(2,3,4-tetra-O-benzyl-β-D-glucopyranosyl)-2,3,6-tri-O-benzyl-D-glucopyranose
  参考文献：
  名称：

  Sugawara, Fumio; Nakayama, Haruhiko; Stroebel, Gary A., Agricultural and Biological Chemistry, 1986, vol. 50, # 9, p. 2261 - 2272

  摘要：

  DOI：

文献信息

• Self‐Promoted Glycosylation for the Synthesis of β‐ <i>N</i> ‐Glycosyl Sulfonyl Amides
  作者：Patrycja Mała、Christian Marcus Pedersen

  DOI：10.1002/ejoc.202100808

  日期：2021.11.8

  Glycosyl sulfonyl amides are synthesized in a self-promoted N-glycosylation with high β-selectivity and in high yields. Armed and disarmed glycosyl donors of different size and with different protective groups react smoothly with sulfonyl amides, such as protected asparagine derivatives. Influence of solvents, concentration, temperature and stoichiometry is studied.

  糖基磺酰酰胺是通过自我促进的N-糖基化合成的，具有高 β-选择性和高产率。不同大小和不同保护基团的武装和解除武装的糖基供体可与磺酰胺（例如受保护的天冬酰胺衍生物）顺利反应。研究了溶剂、浓度、温度和化学计量的影响。
• Regioselective Anomeric <i>O</i> ‐Benzyl Deprotection in Carbohydrates
  作者：Perali Ramu Sridhar、Bandi Anjaneyulu、Boddu Umamaheswara Rao

  DOI：10.1002/ejoc.202101033

  日期：2021.11.8

  A simple and highly regioselective hydrogenolysis of the anomeric benzyl group is reported. The generality and the scope of the reaction were evaluated by applying it to a number of diversly protected benzyl monosaccharides and disaccharides that lead to the formation of the corresponding hemiacetals in good yield.

  报道了异头苄基的简单且高度区域选择性的氢解。反应的一般性和范围是通过将其应用于许多不同保护的苄基单糖和二糖来评估的，这些苄基单糖和二糖导致以良好的产率形成相应的半缩醛。
• Medicinal Composition Containing Diabeted Remedy
  申请人：Izumi Masanori

  公开号：US20080039367A1

  公开（公告）日：2008-02-14

  A pharmaceutical composition effective for the prophylaxis and treatment of diabetes is provided. This pharmaceutical composition comprises the combination of an α-amylase inhibitor selected from a compound represented by the following general formula (I): [wherein A represents, for example, a cyclic group, etc. R 1 and R 2 represent an alkyl group, hydroxymethyl group, etc., and n represents 1 or 2], or a pharmacologically acceptable salt or ester thereof, and at least one type of drug selected from an insulin sensitizer, an insulin secretagogue, a biguanide drug, an insulin preparation and a DPP-IV inhibitor.

  提供一种用于预防和治疗糖尿病的药物组合物。该药物组合物包括以下通用式（I）所表示的化合物中选择的α-淀粉酶抑制剂：[其中A代表环状基团等，R1和R2代表烷基、羟甲基基团等，n代表1或2]，或其药理学上可接受的盐或酯，以及选择自胰岛素增敏剂、胰岛素分泌促进剂、双胍类药物、胰岛素制剂和DPP-IV抑制剂中的至少一种药物。
• Oligosaccharide Derivative
  申请人：Honda Takeshi

  公开号：US20080194495A1

  公开（公告）日：2008-08-14

  Compounds having the formula (I): wherein A represents a group such as a cyclic group, R 1 and R 2 represent groups such as alkyl groups or hydroxymethyl groups, and n represents 1 or 2, or pharmacologically acceptable salts thereof or pharmacologically acceptable esters thereof have superior activity and stability, and are useful for the treatment and/or prevention of diabetes mellitus, or the like.

  具有式(I)的化合物：其中A表示环状基团，R1和R2表示烷基或羟甲基等基团，n表示1或2，或其药学上可接受的盐或酯，在活性和稳定性方面具有优越性，可用于治疗和/或预防糖尿病等疾病。
• MEDICINAL COMPOSITION CONTAINING DIABETES REMEDY
  申请人：Sankyo Company, Limited

  公开号：EP1792620A1

  公开（公告）日：2007-06-06

  A pharmaceutical composition effective for the prophylaxis and treatment of, diabetes is provided. This pharmaceutical composition comprises the combination of an α-amylase inhibitor selected from a compound represented by the following general formula (I): [wherein A represents, for example, a cyclic group, etc. R1 and R2 represent an alkyl group, hydroxymethyl group, etc., and n represents 1 or 2], or a pharmacologically acceptable salt or ester thereof, and at least one type of drug selected from an insulin sensitizer, an insulin secretagogue, a biguanide drug, an insulin preparation and a DPP-IV inhibitor.

  本发明提供了一种有效预防和治疗糖尿病的药物组合物。这种药物组合物包括一种α-淀粉酶抑制剂，该抑制剂选自以下通式（I）所代表的化合物： [其中 A 代表环状基团等。 R1和R2代表烷基、羟甲基等，n代表1或2]，或其药理上可接受的盐或酯，以及至少一种选自胰岛素增敏剂、胰岛素促泌剂、双胍类药物、胰岛素制剂和DPP-IV抑制剂的药物。